Mezokatin Injection (L-Carnitine)

Adult administration

1. Primary and secondary carnitine deficiency Myocardial metabolic disorder due to ischemic heart disease: angina pectoris, acute myocardial infarction Adults: Administer 2~3 grams of L-carnitine daily in 2~3 divided doses by intramuscular or intravenous injection. Adjust the dose appropriately according to age and symptoms. 2. Treatment of carnitine deficiency in patients with end-stage renal disease undergoing hemodialysis Initially, administer 10~20 milligrams/kilogram intravenously over 2~3 minutes at the end of each hemodialysis session. However, the dose may be adjusted according to the plasma L-carnitine level before hemodialysis.

This medication may have glass particles contaminating during the process of cutting the ampoule for injection, therefore care should be taken while cutting. Extra caution is needed when using in children and the elderly. It should not be used in patients with known allergy to this medication. Adverse reactions such as temporary nausea or vomiting, changes in body odor, and gastritis may occur upon usage. In patients with a history of seizures, seizures may occur more frequently or be more severe, so caution is required. Among the patients who received this medication, various side effects such as abdominal pain, allergic reactions, weakness, low back pain, chest pain, fever, headache, infection, and pain at the injection site have been reported. Cardiovascular issues, gastrointestinal problems, blood abnormalities, and neurological symptoms may also occur, so immediate consultation with medical personnel is necessary if any abnormal symptoms appear. The safety and effectiveness of this medication have not been fully established in patients with severely impaired kidney function or those undergoing dialysis. Caution is required when using high doses for extended periods as toxic substances may accumulate in the body. If this medication is used in conjunction with anticoagulants such as warfarin, changes in blood coagulation levels may occur, so regular blood tests should be conducted to monitor the condition. Women who are pregnant or may become pregnant should only use this medication when the benefits of treatment are believed to outweigh the risks. Nursing mothers should carefully decide whether to continue breastfeeding or discontinue medication as it is uncertain whether this medication is excreted in breast milk.

• Transient zone
• vomiting
• body odor
• gastritis
• seizures
• abdominal pain
• accidental injury
• allergic reactions
• weakness
• back pain

This medication is sensitive to light, so it should be stored in a dark container that prevents light exposure. Additionally, it is best to store at room temperature between 1 to 30 degrees Celsius. This will help maintain the effectiveness of the medication.

Appearance

A clear liquid that is colorless to light yellow in a brown transparent ampoule

Package unit

10 ampoules/box [(10 milliliters/ampoule × 10)]